|
Arecor collaborates with pharmaceutical and biotech companies who are developing recombinant proteins and vaccines for application in drugs, medical devices or diagnostics. Arecor has developed Arestat™, a smart stabilization technology, which enables the formulation of labile proteins and vaccines as stable aqueous or dry preparations even at high concentrations or in the presence of ionizing radiation. As a simple reformulation, the technology can be readily integrated into existing manufacturing processes. Arestat™ does not involve the covalent modification of biologics and uses only GRAS (Generally Regarded As Safe) excipients approved by relevant regulatory authorities.
Arestat™ has a proven track record and has been incorporated into a Class 3 medical device (OxyzymeTM) approved in the EU and Canada. It is currently being applied to several recombinant biologics in various stages of development for administration via parenteral, ocular and transdermal routes. |
|
ArestatTM comprises two fundamentally different aspects of our platform stabilization technology. Both utilize excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability
Both platform technologies are available for licensing for applications involving therapeutic proteins, vaccines, medical devices and diagnostics
|
